Genetic Info Helps Clarify Risk of Hereditary Breast Cancer

NEW YORK (GenomeWeb) – Incorporating some well-known genetic risk factors when assessing a woman's risk of non-BRCA-associated hereditary breast cancer can help to more accurately predict risk than just family history alone, according to a study published this week in Genetics in Medicine.

Researchers from the University of Utah and elsewhere used 24 well-known breast cancer risk SNPs that are not in the BRCA1 or BRCA2 genes to come up with a risk score for 4,365 women from two familial breast cancer cohorts, and compared that to a risk score based on family history alone.

The goal of the study was to see whether this panel of 24 SNPs could help to better stratify women already considered to be at an elevated risk due to family history in order to determine which women should receive additional screening, such as magnetic resonance imaging.

The study examined women from two different cohorts: the Breast Cancer Family Registry (BCFR) and the Kathleen Cuningham Consortium Foundation for Research into Familial Breast Cancer (kConFab) cohorts, and included women who had already been diagnosed with breast cancer as well as unaffected women.

The researchers genotyped the women using either capture-based next-generation sequencing, or a SNP genotyping array. They then generated a risk score based on the presence or absence of the SNP, its allele frequency, and the relative risk associated with it.

Next, they used a model called BOADICEA to predict breast cancer risk in 18,000 unaffected women from the two cohorts. The BOADICEA tool predicts a woman's risk of breast and ovarian cancers for 10 years and until the age of 80.

Looking at the genetic risk scores of the 2,869 women who were unaffected and the 1,496 women who were affected with breast cancer, the researchers found "highly significant" differences. Unaffected women had a mean genetic risk score of 2.170, slightly higher than their theoretical risk score of 2.123 based on having a positive family history. Affected women, meantime, had a risk score of 2.25. The unaffected women were followed for an average of 7.4 years, during which time 205 of them developed breast cancer.

Next, the researchers wanted to see the impact of combining the genetic risk scores with the family-history-based risk scores. The US recommends that women with a greater than 20 percent lifetime risk of breast cancer get MRI screening along with mammograms, while in the UK the threshold for MRI screening is 25 percent.

When the researchers added in risk assessment based on genetics to the family-history-based assessment, they noted that 249 of 1,585 women, or 16 percent, who were below the 20 percent risk threshold, moved above that. When using the higher threshold of 25 percent and including both genetic and family history-based risk assessments, 232 out of 2,176 women, or 11 percent, would move above the threshold.

"Inclusion of risk scores based on [breast cancer]-associated SNPs in risk assessment can provide more accurate risk prediction than family history alone and can influence recommendations for cancer screening and prevention modalities for high-risk women," the authors wrote.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

Aug
20
Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.